{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:27:26Z","timestamp":1793852846107,"version":"4.6.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR152516"],"award-info":[{"award-number":["NIHR152516"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jclinepi.2026.112467","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:50:48Z","timestamp":1786690248000},"page":"112467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A conceptual framework for addressing treatment withdrawal effects across the evidence pathway"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-9616","authenticated-orcid":false,"given":"Alexander G.","family":"Mathioudakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Kontopantelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2026.112467_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101181","article-title":"Withdrawal effects following treatment discontinuation: a blind spot in evidence-based medicine","volume":"7","author":"Mathioudakis","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.jclinepi.2026.112467_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.111.183285","article-title":"Drug discontinuation effects are part of the pharmacology of a drug","volume":"339","author":"Reidenberg","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jclinepi.2026.112467_bib3","series-title":"StatPearls","article-title":"Withdrawal syndromes","author":"Regina","year":"2025"},{"issue":"7","key":"10.1016\/j.jclinepi.2026.112467_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis","volume":"11","author":"Henssler","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"10.1016\/j.jclinepi.2026.112467_bib5","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.4065\/77.12.1378","article-title":"Antiepileptic drug withdrawal: literature review","volume":"77","author":"Britton","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.jclinepi.2026.112467_bib6","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41380-024-02445-4","article-title":"Discontinuation of psychotropic medication: a synthesis of evidence across medication classes","volume":"29","author":"Vinkers","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jclinepi.2026.112467_bib7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/CIRCULATIONAHA.117.028321","article-title":"Low-Dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort Study","volume":"136","author":"Sundstrom","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jclinepi.2026.112467_bib8","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112467_bib9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/ijms21020512","article-title":"\u03b2-blockers reverse agonist-induced \u03b22-AR downregulation regardless of their signaling profile","volume":"21","author":"Maccari","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jclinepi.2026.112467_bib10","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.1990.03440120075040","article-title":"The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers","volume":"263","author":"Psaty","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2026.112467_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/thorax-2025-223282","article-title":"Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial","volume":"81","author":"Mathioudakis","year":"2025","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112467_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1752-699X.2010.00198.x","article-title":"Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study","volume":"5","author":"Vestbo","year":"2011","journal-title":"Clin Respir J"},{"key":"10.1016\/j.jclinepi.2026.112467_bib13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","article-title":"European Society of endocrinology and endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"109","author":"Beuschlein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jclinepi.2026.112467_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.jclinepi.2026.112467_bib15","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.3390\/ijms25105459","article-title":"Rebound acid hypersecretion after withdrawal of long-term Proton Pump Inhibitor (PPI) treatment-are PPIs addictive?","volume":"25","author":"Namikawa","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jclinepi.2026.112467_bib16","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.0000012530.68333.C8","article-title":"Withdrawal of statins increases event rates in patients with acute coronary syndromes","volume":"105","author":"Heeschen","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jclinepi.2026.112467_bib17","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41380-024-02782-4","article-title":"Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review","volume":"30","author":"Zhang","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"6","key":"10.1016\/j.jclinepi.2026.112467_bib18","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/jgs.19457","article-title":"Criteria to report adverse drug withdrawal events in clinical trials: a systematic review","volume":"73","author":"Lee","year":"2025","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jclinepi.2026.112467_bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/HYPERTENSIONAHA.111.171074","article-title":"Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study","volume":"58","author":"van Onzenoort","year":"2011","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.jclinepi.2026.112467_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bcp.14240","article-title":"How the EMERGE guideline on medication adherence can improve the quality of clinical trials","volume":"86","author":"Eliasson","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jclinepi.2026.112467_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024886","article-title":"Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis","volume":"9","author":"Munkholm","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jclinepi.2026.112467_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1017\/cts.2017.2","article-title":"Maintenance efficacy designs in psychiatry: randomized discontinuation trials - enriched but not better","volume":"1","author":"Ghaemi","year":"2017","journal-title":"J Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112467_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000496733","article-title":"Discontinuing psychotropic drugs from participants in randomized controlled trials: a systematic review","volume":"88","author":"Cohen","year":"2019","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.jclinepi.2026.112467_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320964097","article-title":"Withdrawal effects confounding in clinical trials: another sign of a needed paradigm shift in psychopharmacology research","volume":"10","author":"Cohen","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jclinepi.2026.112467_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320921694","article-title":"How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding","volume":"10","author":"Hengartner","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jclinepi.2026.112467_bib26","article-title":"Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults","volume":"4","author":"Van Leeuwen","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112467_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000497334","article-title":"Effects of treatment discontinuation in clinical psychopharmacology","volume":"88","author":"Baldessarini","year":"2019","journal-title":"Psychother Psychosom"},{"issue":"96","key":"10.1016\/j.jclinepi.2026.112467_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09059180.05.00009604","article-title":"Patient adherence with COPD therapy","volume":"14","author":"Rand","year":"2005","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112467_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jebm.12600","article-title":"Handling time-varying treatments in observational studies: a scoping review and recommendations","volume":"17","author":"Xu","year":"2024","journal-title":"J Evid Based Med"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112467_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000496734","article-title":"Withdrawal confounding in randomized controlled trials of antipsychotic, antidepressant, and stimulant drugs, 2000-2017","volume":"88","author":"Recalt","year":"2019","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.jclinepi.2026.112467_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116497","article-title":"Antidepressants withdrawal effects and duration of use: a survey of patients enrolled in primary care psychotherapy services","volume":"350","author":"Horowitz","year":"2025","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1016\/j.jclinepi.2026.112467_bib32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","article-title":"Tapering of SSRI treatment to mitigate withdrawal symptoms","volume":"6","author":"Horowitz","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.jclinepi.2026.112467_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1192\/bja.2021.62","article-title":"Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies","volume":"28","author":"Horowitz","year":"2022","journal-title":"BJPsych Adv"},{"key":"10.1016\/j.jclinepi.2026.112467_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1991.01810280029004","article-title":"Methodologic issues in maintenance therapy clinical trials","volume":"48","author":"Greenhouse","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jclinepi.2026.112467_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211032051","article-title":"Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA","volume":"11","author":"Hengartner","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jclinepi.2026.112467_bib36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/M20-0882","article-title":"Delayed denosumab injections and fracture risk among patients with osteoporosis : a population-based cohort Study","volume":"173","author":"Lyu","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2026.112467_bib37","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2026.112467_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320980573","article-title":"Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum","volume":"10","author":"Hengartner","year":"2020","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626003434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626003434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:06:01Z","timestamp":1793851561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435626003434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S0895435626003434"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112467","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A conceptual framework for addressing treatment withdrawal effects across the evidence pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112467"}}